Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
Oncotarget: Mutational Burden in Lung Cancer Studied in Multisite Cohort
FOR IMMEDIATE RELEASE 2022-04-25
In a trending new research paper published in Oncotarget, researchers conducted a multi-site cohort study of tumor mutational burden among hundreds of patients diagnosed with stage IV non-small cell lung cancer.
This multidisciplinary research team analyzed tumor mutational burden (TMB) among a large cohort of patients who had been diagnosed with stage IV non-small cell lung cancer (NSCLC). The cohort included 667 patients recruited from nine different academic and community cancer centers across the United States.
“The purpose of this study is to evaluate clinical outcomes by TMB among NSCLC patients treated with immunotherapy containing regimens in the first-line setting.” (Source, 2022)
While having a high TMB may sound unfavorable, a higher TMB has been associated with a higher number of neoantigens. The presence of a greater number of neoantigens may potentiate a stronger immune response. Thus, TMB may be a viable biomarker of tumor response to immuno-oncology agents.
“Based on the results in this study and prior research, TMB along with other biomarkers, such as PD-L1, may help identify patients more likely to benefit from first-line immunotherapy.” (Source, 2022)
Results of the study confirmed the association between a higher TMB and smoking history. However, the study did not show an association between TMB and sex, age or tumor histology. The team found that, among patients treated with first-line immunotherapy, TMB levels greater than or equal to 10 mutations per megabase were significantly associated with improved overall survival and progression-free survival.
About Oncotarget:Oncotarget(a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
